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Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, is a common condition
associated with a significant clinical and economic burden. Anticoagulant therapy is the mainstay of treatment for VTE,
having been shown to reduce the risk of death in patients with pulmonary embolism, and recurrence or extension of
thrombi in patients with deep vein thrombosis during the initial treatment period. Long-term anticoagulation is
indicated in some individuals with VTE, depending on individual risk of VTE recurrence and anticoagulant-related
bleeding. Management of VTE in clinical practice is often complex because patients’ characteristics and treatment
needs may differ considerably from those encountered in clinical trials. Current guidelines recommend the use of
either low molecular weight heparins or fondaparinux overlapping with and followed by a vitamin K antagonist
for the initial treatment of VTE, with the vitamin K antagonist continued when long-term anticoagulation is required.
These traditional anticoagulants have practical limitations that have led to the development of direct oral anticoagulants
that directly target either Factor Xa or thrombin and are administered at a fixed dose without the need for
routine coagulation monitoring. This review discusses practical considerations for hospital physicians and haematologists
in the management of VTE treatment, including the potential for the direct oral anticoagulants to simplify treatment.
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Venous thromboembolism (VTE), comprising deep vein
thrombosis (DVT) and pulmonary embolism (PE), is the
third most common cardiovascular disease after myo-
cardial infarction and stroke [1], and hence a significant
cause of morbidity and mortality worldwide. The esti-
mated annual incidence of VTE is one to two cases per
1000 in the general population, although annual inci-
dences as high as four per 1000 have been reported
[2,3]. Potentially, the true incidence of VTE is under-
reported, because of the failure to identify silent PE ante
mortem and the falling rate of autopsy [2,4-6]. VTE is as-
sociated with a significant economic burden owing to its
prevalence, cost of treatment, and potential for recurrence
and long-term complications. VTE-related healthcare
costs in the US alone have been variously estimated at be-
tween $2 billion and $10 billion per year [2,3,7,8].
VTE occurs in men and women of all ethnicities and
ages, although incidence rates vary between groups andCorrespondence: simon.mcrae@health.sa.gov.au
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unless otherwise stated.are considerably higher among the elderly [5,9]. The in-
cidence, and hence associated cost, of VTE is likely to
increase in many societies because of an ageing popula-
tion [3]. In the US, the first incidence of VTE was
shown to rise exponentially from <5 cases per 100,000
persons <15 years of age to ~500 cases (0.5%) per 100,000
persons at age 80 years [5], and studies across Asia and
Europe demonstrate a similar trend [10-12].
Known risk factors for VTE are listed in Table 1.
Identification of at-risk individuals and use of appropri-
ate thromboprophylactic measures has been shown to
reduce the incidence of VTE [4,13]; however, use
of thromboprophylaxis remains suboptimal [13-15].
Furthermore, 25–50% of VTE cases occur in the
absence of an identifiable risk factor and are considered
unprovoked [2]. Therefore, even with optimal use of
thromboprophylaxis, the community burden of VTE
will remain significant, and optimal treatment to
minimize morbidity and mortality associated with the
condition will remain important.
This article provides an overview of the practical consid-
erations involved in initial and long-term management ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Risk factors for venous thromboembolism
[2,16-19]
Genetic
Factor V Leiden Prothrombin G20210A
Antithrombin deficiency Prothrombin C deficiency
Family history of venous thromboembolism Prothrombin S deficiency
Hyperhomocysteinaemia Sickle cell trait
Acquired, non-transient
Increased age Spinal cord injury
Obesity Prior venous
thromboembolism
Chronic medical illness Central venous lines
Cancer Transvenous pacemaker














Red blood cell transfusion
darbepoietin-alpha
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potential impact of direct oral anticoagulants on the
management of VTE.
Initial management of venous thromboembolism
It has been suggested recently that treatment of VTE
can be divided into two phases: an initial “active treat-
ment” phase of 3 months and a subsequent “secondary
prevention phase” [20]. Anticoagulation during the ini-
tial treatment period has been shown to reduce the risk
of initial or additional embolization in patients with
proximal DVT or PE, and to reduce the risk of death in
patients with PE [21,22]. Suboptimal anticoagulation
during this initial 3-month period has been associated
with an increased risk of recurrent thrombosis [23], with
the risk highest if anticoagulation is inadequate during
the first month of treatment [24]. Therefore, anti-
coagulation is the mainstay of the initial treatment of VTE.
The American College of Chest Physicians (ACCP)
guidelines, the most widely accepted recommendations
on VTE treatment, recommend that patients with acute
proximal DVT or PE receive an initial standard anti-
coagulant regimen consisting of the administration of a
parenteral anticoagulant (subcutaneous [s.c.] low mo-
lecular weight heparin [LMWH] or fondaparinux, or
intravenous [i.v.] or s.c. unfractionated heparin [UFH])for at least 5 days, with early initiation of a vitamin K
antagonist (VKA) such as warfarin [25]. According to
European guidelines, parenteral anticoagulation should
be continued until an international normalized ratio
(INR) of at least 2.0 has been achieved on 2 consecutive
days, because of the slow onset of action of the anti-
thrombotic effect of VKAs [26]. Although there is evi-
dence that initial use of LMWH is associated with a
lower risk of recurrent thrombosis, major bleeding and
mortality compared with i.v. UFH [27], the recommen-
dation and widespread adoption of LMWHs as the agent
of choice has also been driven by the ability to adminis-
ter them at a fixed weight-based s.c. dose, thereby allow-
ing outpatient therapy in low-risk patients.
In patients with proximal DVT or PE, anticoagulant
treatment is recommended to be continued for at least
3 months [25]. A shorter duration of therapeutic anti-
coagulation than this is associated with an increase in
the risk of recurrent thrombosis, which in turn increases
the risk of the chronic complications of post-thrombotic
syndrome (PTS) and chronic thromboembolic pulmon-
ary hypertension. In patients with provoked isolated dis-
tal DVT, anticoagulation can probably be stopped after a
shorter duration of 4–6 weeks without increasing the
risk of recurrent events [25]. The decision to prolong
anticoagulation past this initial 3-month treatment
period is determined by the balance between the risk of
bleeding with ongoing anticoagulation and the risk of re-
current thrombosis in patients who stop taking anti-
coagulant therapy. Factors influencing this decision and
alternative long-term anticoagulant options will be dis-
cussed in a subsequent section.
Although the above treatment strategy of an initial
parenteral anticoagulant overlapped with and followed
by a VKA for a minimum of 3 months is generally safe
and effective, with a rate of recurrent VTE of 3–4% and
a major bleeding rate of ~1% [27], this approach has
known limitations. The requirement for the initial use of
a parenteral anticoagulant has practical implications,
and requires additional resource utilization when a pa-
tient cannot self-inject, but is otherwise suitable for
home therapy. Because of the narrow therapeutic win-
dow and variable dose response, influenced by both gen-
etic and environmental factors [28,29], warfarin and
other VKAs require regular coagulation monitoring and
dose adjustment to maintain an INR within the thera-
peutic range (INR 2.0–3.0), complicating their use in
day-to-day care [30]. It has been suggested that patient
self-testing and self-management of VKA therapy has
the potential to improve clinical outcomes through im-
provements in time spent in therapeutic range and re-
duce healthcare resource utilization. In a systematic
review of studies enrolling patients receiving warfarin
for a number of indications, self-testing using a point-of-
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using a pre-set algorithm significantly reduced the rate
of major thrombotic complications compared with
standard laboratory-based monitoring, with no signifi-
cant difference in the rate of major bleeding or all-
cause mortality. Self-testing alone did not result in a
significant change in thromboembolic outcomes and
did not have such a high impact on cost savings [31].
Nonetheless, not all patients are suitable for self-
management of VKA therapy (such as the very elderly),
and selected patients must be highly motivated and
trained appropriately [31].
Direct oral anticoagulants for the initial treatment of
venous thromboembolism
The above practical limitations of traditional anti-
coagulants have helped to drive the development and
evaluation in large phase III trials of direct oral anti-
coagulants, which have a more predictable anticoagulant
effect allowing for fixed-dose administration without the
need for routine coagulation monitoring or dose adjust-
ment. These agents directly target specific steps in the
coagulation cascade and inhibit either Factor Xa (rivaroxa-
ban, apixaban and edoxaban) or thrombin (dabigatran).
All have been evaluated for the initial treatment or long-
term prevention of VTE in phase III studies. Rivaroxaban,
dabigatran and apixaban have been approved for the treat-
ment of DVT and PE, and the prevention of recurrent
DVT and PE, in adults in the European Union and the US.
Edoxaban is approved for this indication in Japan, and it is
reasonable to assume that it will receive wider approval
for VTE treatment in the future (Table 2).
Rivaroxaban
Rivaroxaban is an oral, direct Factor Xa inhibitor with a
rapid onset of action (maximum inhibition of Factor
Xa achieved 2–4 hours post-dose) and a half-life of
5–13 hours in healthy individuals [40]. Approximately
one-third of the rivaroxaban dose is excreted as un-
changed drug in the urine, with the remainder of the
drug metabolized and eliminated renally or by the
hepatobiliary route.
Rivaroxaban has been evaluated for the initial treat-
ment of VTE in the EINSTEIN DVT and EINSTEIN PE
studies [32,33]. Both of these phase III studies were
open-label, randomized, event-driven, non-inferiority
studies in patients with symptomatic DVT or PE, compar-
ing the single-drug approach with rivaroxaban (15 mg
twice daily [bid] for 3 weeks then 20 mg once daily [od])
with a standard regimen of s.c. enoxaparin 1 mg/kg bid
for at least 5 days overlapped with a VKA (warfarin or ace-
nocoumarol) until the INR was at least 2.0 for 2 consecu-
tive days. Rivaroxaban or VKA therapy was continued for
3, 6 or 12 months [32,33].In both the EINSTEIN DVT and EINSTEIN PE studies,
rivaroxaban was non-inferior to the standard enoxaparin/
VKA regimen in preventing VTE recurrence (Table 2). In
EINSTEIN DVT, the primary efficacy endpoint occurred
in 2.1% of patients in the rivaroxaban group versus 3.0% of
patients in the standard therapy group (hazard ratio [HR]
0.68; 95% confidence interval [CI] 0.44–1.04). Similarly, in
EINSTEIN PE, the primary efficacy endpoint occurred in
2.1% of patients in the rivaroxaban group versus 1.8% of
patients in the standard therapy group (HR 1.12; 95% CI
0.75–1.68). The incidence of the principal safety outcome
of major or non-major clinically relevant bleeding was
similar in patients receiving rivaroxaban compared with
those receiving standard therapy in both studies (Table 2)
[32,33]. The rate of major bleeding was significantly lower
for rivaroxaban compared with standard therapy (1.1% vs
2.2%; p = 0.003) in EINSTEIN PE and was not significantly
different in EINSTEIN DVT (0.8% vs 1.2%; p = 0.21).
A prespecified pooled analysis of the EINSTEIN DVT
and EINSTEIN PE studies including more than 8000 pa-
tients permitted evaluation of clinically important sub-
groups and rare safety events [41]. The non-inferiority of
rivaroxaban to standard therapy was confirmed (2.1% vs
2.3%; HR 0.89; 95% CI 0.66–1.19; p < 0.001), with a similar
incidence of major and non-major clinically relevant bleed-
ing (9.4% vs 10%; HR 0.93; 95% CI 0.81–1.06; p = 0.27), and
importantly, a 46% relative risk reduction in major bleeding
(1.0% vs 1.7%; HR 0.54; 95% CI 0.37–0.79; p = 0.002). Rivar-
oxaban also showed consistent efficacy and safety across
key patient subgroups, irrespective of fragility, cancer or
clot severity [41].
Apixaban
Apixaban is also an oral, direct Factor Xa inhibitor with a
rapid onset and offset of action (half-life of ~12 hours
after repeated dosing), with ~27% of the drug dose cleared
renally [42]. The large phase III AMPLIFY trial evaluated
apixaban for the initial treatment of VTE [34]. In this
study, patients with symptomatic proximal DVT or PE
were randomized to either monotherapy with apixaban
(10 mg bid for 7 days, then 5 mg bid for 6 months) or a
standard enoxaparin/warfarin regimen (s.c. enoxaparin
1 mg/kg bid until INR ≥2.0; warfarin od). Apixaban was
shown to be non-inferior to standard therapy in prevent-
ing VTE recurrence or VTE-related death (2.3% vs 2.7%;
relative risk [RR] 0.84; 95% CI 0.60–1.18). Apixaban was
associated with a significant reduction in the principal
safety outcome of major bleeding compared with stand-
ard therapy (0.6% vs 1.8%; RR 0.31; 95% CI 0.17–0.55;
p < 0.001; Table 2). The composite of major and non-
major clinically relevant bleeding events was also signifi-
cantly lower after treatment with apixaban compared with
standard therapy (4.3% vs 9.7%; RR 0.44; 95% CI 0.36–0.55;
p < 0.001) [34].
Table 2 Phase III trials of direct oral anticoagulants in the treatment of venous thromboembolism [32-38]







Rivaroxaban 15 mg bid for 3 weeks, then
20 mg od for 3–12 months
or
Enoxaparin for ≥5 days with VKA
(target INR 2.0–3.0) for 3–12 months
VTE recurrence for rivaroxaban vs LMWH/VKA 2.1%
vs 3.0% (HR 0.68; 95% CI 0.44–1.04; p < 0.001 for
non-inferiority; p = 0.08 for superiority). Major or
non-major clinically relevant bleeding for rivaroxaban
vs LMWH/VKA 8.1% vs 8.1% (HR 0.97; 95% CI







Rivaroxaban 15 mg bid for 3 weeks, then
20 mg od for 3–12 months
or
Enoxaparin for ≥5 days with VKA (target INR
2.0–3.0) for 3–12 months
VTE recurrence for rivaroxaban vs LMWH/VKA
2.1% vs 1.8% (HR 1.12; 95% CI 0.75–1.68; p = 0.003
for non-inferiority). Major or non-major clinically
relevant bleeding for rivaroxaban vs LMWH/VKA






After completion of 6–12 months’ treatment:
Rivaroxaban 20 mg od for 6 or 12 months
or
Placebo for 6 or 12 months
VTE recurrence for rivaroxaban vs placebo 1.3% vs
7.1% (HR 0.18; 95% CI 0.09–0.39; p < 0.001 for
superiority). Major bleeding for rivaroxaban vs




AMPLIFY Apixaban 10 mg bid for 7 days then 5 mg
bid for 6 months
or
Enoxaparin 1 mg/kg (s.c.) bid until INR ≥2,
warfarin (target INR 2.0–3.0)
VTE recurrence or VTE-related death for apixaban vs
LMWH/warfarin 2.3% vs 2.7% (RR 0.84; 95% CI
0.60–1.18; p < 0.001 for non-inferiority for apixaban).
Major bleeding for apixaban vs LMWH/warfarin
0.6% vs 1.8% (RR 0.31; 95% CI 0.17–0.55; p < 0.001






After 6–12 months of apixaban or warfarin:
Apixaban 2.5 mg or 5 mg bid for 12 months
or
Placebo for 12 months
VTE recurrence or any-cause death for apixaban
2.5 mg or 5.0 mg vs placebo, 3.8% or 4.2% vs 11.6%
(2.5 mg RR 0.33; 95% CI 0.22–0.48; 5 mg RR 0.36; 95%
CI 0.25–0.53; p < 0.001 for superiority for both
apixaban doses). Major bleeding for apixaban 2.5 mg
or 5.0 mg vs placebo, 0.2% (RR 0.49; 95% CI 0.09–2.64)
or 0.1% (RR 0.25; 95% CI 0.03–2.24) vs 0.5%






LMWH or UFH for ≥5 days then edoxaban
60 mg od for 3–12 months
or
LMWH or UFH for ≥5 days then warfarin
(target INR 2.0–3.0) for 3–12 months
VTE recurrence or VTE-related death for edoxaban vs
warfarin 3.2% vs 3.5% (HR 0.89; 95% CI 0.70–1.13;
p < 0.001 for non-inferiority for edoxaban). First major
or non-major clinically relevant bleeding event 8.5%







Edoxaban 90 mg od for 10 days then
60 mg od (total 90 days)
or
Warfarin (target INR 2.0–3.0) for 90 days, with






RE-COVER [35] LMWH or UFH for ≥5 days; dabigatran
150 mg bid for 6 months
or
LMWH or UFH for ≥5 days; warfarin
(target INR 2.0–3.0) for 6 months
VTE recurrence for dabigatran vs warfarin 2.4% vs
2.1% (HR 1.10; 95% CI 0.65–1.84; p < 0.001 for
non-inferiority). Major bleeding for dabigatran vs







LMWH or UFH for 5–11 days; dabigatran
150 mg bid for 6 months
or
LMWH or UFH for 5–11 days; warfarin
(target INR 2.0–3.0) for 6 months
VTE recurrence or VTE-related death for dabigatran
vs warfarin 2.3% vs 2.2% (HR 1.08; 95% CI
0.64–1.80; p < 0.001 for non-inferiority)*. Major
bleeding for dabigatran vs warfarin 1.2% vs




RE-MEDY [38] After 3–12 months of anticoagulant therapy:
Dabigatran 150 mg bid for 6–36 months
or
Warfarin (target INR 2.0–3.0) for 6–36 months
VTE recurrence for dabigatran vs warfarin 1.8% vs 1.3%
(HR 1.44; 95% CI 0.78–2.64; p = 0.01 for non-inferiority).
Major bleeding for dabigatran vs warfarin 0.9% vs






After 6–18 months of anticoagulant therapy:
Dabigatran 150 mg bid for 6 months
or
Placebo for 6 months
VTE recurrence for dabigatran vs placebo 0.4% vs
5.6% (HR 0.08; 95% CI 0.02–0.25; p < 0.001).
Major bleeding for dabigatran vs placebo 0.39%
vs 0% (HR not available; 95% CI 0.04–1.05; p = 0.5)
*During 6 months of treatment, excluding the additional 30-day follow-up.
Abbreviations: bid twice daily, CI confidence interval, DVT deep vein thrombosis, HR hazard ratio, INR international normalized ratio, LMWH low molecular weight
heparin, NS not significant, od once daily, PE pulmonary embolism, RR relative risk, s.c. subcutaneous, UFH unfractionated heparin, VKA vitamin K antagonist, VTE
venous thromboembolism.
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Edoxaban is another direct Factor Xa inhibitor that was
evaluated in a large phase III clinical trial for use in the
treatment of VTE [39]. It has a rapid onset of action,
reaching maximum plasma concentration within 1–2 hours
of oral administration, and has a half-life of 6–11 hours in
young, healthy individuals after single doses [43]. Renal
excretion accounts for 35–39% of drug metabolism. The
global Hokusai-VTE study randomized patients with
symptomatic DVT and/or PE to up to 12 months’ treat-
ment with either edoxaban (60 mg od) or warfarin (target
INR 2.0–3.0) after an initial treatment period with a
parenteral anticoagulant (s.c. LMWH 1 mg/kg bid or
1.5 mg/kg od, or i.v. UFH, for up to 12 days) [39].
Edoxaban was shown to be non-inferior to standard ther-
apy in preventing VTE recurrence or VTE-related death
(3.2% vs 3.5%; HR 0.89; 95% CI 0.70–1.13; p < 0.001)
(Table 2) and was associated with a significant reduction
in the principal safety outcome of major or non-major
clinically relevant bleeding (8.5% vs 10.3%; HR 0.81; 95%
CI 0.71–0.94; p = 0.004 for superiority). The incidence of
major bleeding was similar between edoxaban and stand-
ard therapy groups (Table 2).
Although all patients received initial treatment with
a parenteral anticoagulant in the Hokusai-VTE study,
the smaller phase II US multicentre study (eTris;
NCT01662908) will compare 90 days’ treatment with
edoxaban monotherapy (90 mg od for ~10 days, then
60 mg od for ~90 days) with a standard heparin/war-
farin regimen for the treatment of symptomatic DVT.
The primary endpoint in this study is magnetic reson-
ance imaging assessment of reduction in thrombus
burden at day 14–21 after commencing treatment. Re-
cruitment is ongoing for this study.
Dabigatran
Dabigatran is a direct thrombin inhibitor that has been
extensively evaluated in phase III studies for the treat-
ment of VTE. Dabigatran is administered orally as the
prodrug dabigatran etexilate and has a rapid onset of
action with peak anticoagulant effect within 2–3 hours
after administration. Dabigatran is predominantly cleared
renally (~85%) and the normal half-life of 12–14 hours
may be prolonged by up to twofold in patients with sig-
nificant renal impairment [44].
Two large phase III trials evaluating dabigatran for the
initial treatment of VTE, RE-COVER and RE-COVER II,
have been completed. In both trials, patients with symp-
tomatic DVT and PE were randomized to either dabiga-
tran 150 mg bid or standard-intensity warfarin after an
initial period of parenteral anticoagulation for a median
of 9 days. Both studies demonstrated dabigatran to be
non-inferior to standard therapy in preventing VTE re-
currence or VTE-related death (2.4% vs 2.1%; HR 1.10;95% CI 0.65–1.84 and 2.3% vs 2.2%; HR 1.08; 95% CI
0.64–1.80 for RE-COVER and RE-COVER II, respect-
ively), with similar rates of major bleeding events (Table 2),
but a significant reduction in major or non-major clinic-
ally relevant bleeding with dabigatran in RE-COVER (5.6%
vs 8.8%; HR 0.63; 95% CI 0.47–0.84; p = 0.002) [35,36].
Efficacy and safety results from the individual
RE-COVER and RE-COVER II studies were confirmed in
a pooled analysis with a combined population of over
5000 patients. The incidence of recurrent VTE was 2.4%
for dabigatran compared with 2.2% for warfarin-treated
patients (HR 1.09; 95% CI 0.76–1.57 during 6 months of
treatment). Dabigatran was also associated with a similar
incidence of major bleeding (1.4% vs 2.0%; HR 0.73; 95% CI
0.48–1.11) and a lower incidence of clinically relevant
bleeding (5.3% vs 8.5%; HR 0.62; 95% CI 0.50–0.76) versus
warfarin. Age was shown to significantly influence the
treatment effect for major or non-major clinically relevant
bleeding events (p = 0.010) (see ‘Treatment of venous
thromboembolism in special populations’). Treatment
effects remained consistent across other patient subgroups,
including in patients with PE or cancer [36].
Comparison of the direct oral anticoagulants with
conventional therapy and each other
To date, the completed trials have reported that rivar-
oxaban, apixaban, edoxaban and dabigatran have simi-
lar efficacy and safety to conventional standard-of-care
anticoagulation. Rivaroxaban demonstrated a signifi-
cantly reduced rate of major bleeding in patients with
PE, and this result was retained in the pooled analysis
of EINSTEIN DVT and EINSTEIN PE data [33,41]. A
significant reduction in major bleeding was also evident
with apixaban in patients with DVT and/or PE [34]. Al-
though edoxaban was associated with a significant reduc-
tion in the composite of major and non-major clinically
relevant bleeding, rates of major bleeding remained similar
between treatment groups [39]. Across all studies, the
time spent in therapeutic range for VKA-treated patients
ranged between 57–64%, a rate that compares favourably
with that seen in patients in the community using standard
monitoring [32-35,39]. Although patient self-monitoring
and self-dose adjustment has been reported to have the po-
tential to improve outcomes in selected patients receiving
warfarin [31], this approach was not used in the comparator
arms of the phase III trials with the direct oral anticoagulants.
The above data have led to both rivaroxaban and
dabigatran being included in the current ACCP guide-
lines for the treatment of VTE, despite only rivaroxa-
ban having been approved for this indication at the
time [25]. Treatment with LMWH and a VKA is weakly
recommended over rivaroxaban and dabigatran, pri-
marily because of the lack of long-term data for these
direct oral anticoagulants at the time of writing; neither
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other [25]. Because the direct oral anticoagulants have dif-
fering pharmacological and pharmacokinetic characteris-
tics, patients may be more suited to one agent than
another based on their own individual characteristics [45].
The results of the phase III trials of the direct oral
anticoagulants cannot be compared directly, and because
head-to-head trials are unlikely, the comparative efficacy
and safety of the different agents is difficult to assess
(Figure 1). Although the inclusion and exclusion criteria
of the different phase III trials had many similarities,
these trials vary in terms of their individual study de-
signs and patient characteristics [46]. The EINSTEIN PE
and EINSTEIN DVT studies of rivaroxaban were open
label, in contrast to the double-blind studies of dabiga-
tran (RE-COVER, RE-COVER II), apixaban (AMPLIFY)
and edoxaban (Hokusai-VTE) [32-35,37-39,47]. Another
significant difference in the trial designs was the planned
use of a single-drug approach with no initial parenteral
anticoagulation in EINSTEIN DVT, EINSTEIN PE and
AMPLIFY [32-34], compared with an initial treatment
period with a parenteral anticoagulant (usually i.v. UFH
or s.c. LMWH) in the RE-COVER and Hokusai-VTE
studies [35,36,39]. In practice, because of the time required
for recruitment, patients in the AMPLIFY and EINSTEIN
studies were allowed to have received up to either 36 hours
[34] or 48 hours [32,33] of parenteral anticoagulation prior
to enrolment, respectively, with the majority receiving
24 hours of pre-study treatment. In an analysis of data from
the EINSTEIN DVT and PE studies, there was no differ-
ence in outcomes between patients who received pre-
randomization heparin and those who did not [48].
A large degree of variation is also seen in the number
of patients with PE enrolled in the acute phase III VTE
studies, and in the anatomical extent of PE at baseline.
The EINSTEIN PE study recruited 4832 patients with
PE (with or without DVT) [33], in comparison to the
AMPLIFY [34] and the combined RE-COVER studies,
which recruited 1836 and 1602 patients with PE, respect-
ively [35,36]. In total, 3319 patients with PE (with or with-
out DVT) were enrolled in the Hokusai-VTE study, and
nearly one-third of these patients had severe PE and right
ventricular dysfunction, as measured by N-terminal frag-
ment of brain natriuretic peptide levels [39]. With regards
to the anatomical extent of PE, extensive PE was defined in
both the EINSTEIN PE and Hokusai-VTE studies as
the involvement of multiple lobes covering at least
25% of the entire vasculature. Extensive PE was ob-
served in 24.2% of patients in EINSTEIN PE com-
pared with 45.8% of patients in Hokusai-VTE [33,39].
In contrast, the AMPLIFY study defined extensive PE
as involving at least two lobes with at least 50% of
vasculature affected for each lobe; 37.2% of patients
met this criteria on presentation [34].Secondary prevention of venous thromboembolism
It has become clear that VTE is best considered a chronic
disease, with patients being at significant risk of recurrent
thrombosis after an initial event. Approximately one-third
of unselected patients with VTE will experience a recur-
rent event within 10 years of their first episode [16,49,50].
Recurrent thrombotic events may be fatal, and non-fatal
events increase the risk of developing chronic complica-
tions of VTE such as PTS and chronic thromboembolic
pulmonary hypertension [7,51].
Depending on the balance between an individual’s risk
of recurrent thrombosis after discontinuation of anti-
coagulation and their risk of bleeding while receiving treat-
ment, continuation of anticoagulation into a “secondary
prevention” phase may be justified after the initial treat-
ment period for VTE [25]. The strongest clinical predictor
of recurrence risk is the circumstance in which the initial
thrombotic event occurred, in particular whether there
was a temporal association with a transient provoking risk
factor. In patients with proximal DVT or PE in whom a
surgical or other major transient risk factor was present,
the risk of recurrence is low, and 3 months’ treatment is
recommended. In patients with either proximal DVT and/
or PE whose initial event was unprovoked, or who have an
ongoing significant persisting risk factor such as cancer, ex-
tended or long-term anticoagulation should be considered,
particularly in patients with a low to moderate risk of bleed-
ing [25]. Additional factors that would support long-term
anticoagulation include male sex, the presence of PTS, sig-
nificant obesity, poor underlying cardiovascular reserve and
a history of more than one prior thrombotic event [52,53].
Direct oral anticoagulants for the secondary prevention of
venous thromboembolism
The level of adherence to treatment guidelines for long-
term management of VTE in the outpatient setting is
unclear [54]. Factors that might limit the acceptance of
extended anticoagulation include the current require-
ment for therapeutic monitoring and dietary restrictions
with warfarin, along with patients’ and clinicians’ percep-
tion of the bleeding risk associated with anticoagulation.
Possibly, more convenient anticoagulant agents with at
least equivalent efficacy and safety may lead to more
widespread acceptance of extended anticoagulation. A
number of studies have evaluated the direct oral anti-
coagulants for the secondary prevention of VTE [32,37,38].
The EINSTEIN EXT study evaluated rivaroxaban for
secondary prevention after initial anticoagulant treat-
ment for 6–12 months, and found that treatment with
rivaroxaban 20 mg od for an additional 6 or 12 months
was associated with a significant 82% reduction in the
relative risk of VTE recurrence compared with placebo,
without a significantly increased risk of major bleeding
(Table 2) [32]. A net clinical benefit, defined as the
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p < 0.001†



























































































































































































Figure 1 Completed phase III trials of direct oral anticoagulants in the treatment of venous thromboembolism. (a) Primary efficacy outcome
and (b) Major bleeding events [32,33,35-39]. *Non-inferiority test. †Superiority test. ‡Principal safety outcome in EINSTEIN DVT and EINSTEIN PE was
major or non-major clinically relevant bleeding. HR, hazard ratio; LMWH, low molecular weight heparin; NS, not significant; RR, relative risk; VKA, vitamin
K antagonist; VTE, venous thromboembolism.
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bleeding, was observed with rivaroxaban compared with
placebo (2.0% vs 7.1%, p < 0.001).
The placebo-controlled AMPLIFY-EXT study assessed
apixaban (2.5 mg bid or 5 mg bid for 12 months) for
secondary prevention of VTE after 6–12 months’ initial
treatment [37]. Symptomatic recurrent VTE or VTE-
related death occurred in significantly fewer patients re-
ceiving apixaban than those given placebo: 73/829 pa-
tients (8.8%) in the placebo arm, 14/840 patients (1.7%)
in the 2.5 mg apixaban arm and 14/813 patients (1.7%)
in the 5 mg apixaban arm (p < 0.001 for both apixaban
doses vs placebo). The rates of major bleeding were
similar for apixaban compared with placebo (2.5 mg group
vs placebo: 0.2% vs 0.5%; RR 0.49; 95% CI 0.09–2.64; 5 mg
group vs placebo: 0.1% vs 0.5%; RR 0.25; 95% CI
0.03–2.24; p-values not reported). For the first time
in a study of secondary prevention of VTE, anti-
coagulant therapy was demonstrated to reduce the
risk of all-cause mortality [37]. The lower apixaban dose
of 2.5 mg bid, the same dose that was used in orthopaedic
prophylaxis studies, appeared to have similar efficacy to
the higher apixaban dose in preventing recurrent throm-
bosis, and the risk of both major and non-major clinically
relevant bleeding did not differ significantly from that ob-
served in patients receiving placebo.
Extended-duration dabigatran treatment has also been
evaluated for the secondary prevention of VTE compared
with both warfarin (RE-MEDY) and placebo (RE-SONATE)
[38]. RE-MEDY demonstrated that dabigatran 150 mg bid
was non-inferior to warfarin in preventing VTE recurrence
after 3–12 months’ prior anticoagulant therapy [38]. There
was a significant reduction in major or non-major clinically
relevant bleeding events and a non-significant reduction in
major bleeding. A higher incidence of acute coronary syn-
drome events was reported in patients receiving dabigatran
in this study (0.9% vs 0.2% for warfarin; p = 0.02). A subse-
quent meta-analysis of nine randomized controlled trials of
dabigatran for a number of indications demonstrated a
modest increase in the risk of myocardial infarction and
acute coronary syndrome with dabigatran compared with
warfarin (odds ratio (OR) 1.30; 95% CI 1.04–1.63;
p = 0.021) but not with apixaban or rivaroxaban [55].
The RE-SONATE study showed that after 6–18 months’
initial anticoagulant therapy, an 82% reduction in recur-
rent or fatal VTE in patients receiving dabigatran 150 mg
bid occurred without an increase in the risk of major
bleeding [38].
All three direct oral anticoagulants evaluated for the
secondary prevention of recurrent VTE appear to be ef-
fective agents for this indication, with an acceptable risk
of bleeding (Figure 1). The choice of agent is likely to be
influenced by availability and individual patient charac-
teristics as discussed below.Treatment of venous thromboembolism in special
populations
Elderly patients
Because the risk of VTE increases exponentially with
age, there is an increasing need for effective treatment in
elderly patients [2,9,16]. In addition, treatment of older
patients is often complicated by co-morbidities, con-
comitant medication and impaired renal function. The
pharmacokinetics of the direct oral anticoagulants are al-
tered in the healthy elderly population compared with in
younger individuals. The half-life of rivaroxaban is pro-
longed in elderly versus younger individuals (11–13 hours
vs 5–9 hours), and there is an approximately two-
fold increase in the area under the concentration–time
curve of dabigatran and a one-third increase in that of
apixaban in older individuals [40,42,44]. There is no rou-
tine requirement for dose adjustment based on age with
rivaroxaban provided renal function is adequate [40], and
the EINSTEIN clinical trial programme did not exclude
elderly patients (age >75 years). In total, the EINSTEIN
DVT and EINSTEIN PE studies included >3000 patients
aged >65 years, ~1300 of whom were aged >75 years
[32,33]. Subgroup analyses from the EINSTEIN DVT and
EINSTEIN PE pooled data showed that fragile patients
(those aged >75 years or with CrCl <50 ml/min or body
weight ≤50 kg) had significantly reduced rates of major
bleeding with rivaroxaban versus enoxaparin/VKA (1.3%
vs 4.5%; HR 0.27; 95% CI 0.13–0.54; p = 0.011); this result
was consistent across the individual components of this
subgroup. The net clinical benefit for patients treated with
rivaroxaban was also higher versus enoxaparin/VKA in
fragile patients (4.6% vs 8.4%; HR 0.51; 95% CI 0.34–0.77;
p = 0.017) [41].
Supplementary information from the RE-COVER,
RE-COVER II, RE-MEDY and RE-SONATE trials states
that 2892 patients aged ≥65 years, including at least 788
patients ≥75 years, were enrolled in these trials [36,38].
Age was shown to have no effect on recurrent VTE or
bleeding outcomes [36,56].
The AMPLIFY-EXT study enrolled 819 patients
aged >65 years, of whom 329 were >75 years [37].
Subgroup analysis suggested similar efficacy of both
the apixaban 2.5 mg and 5.0 mg doses, with a trend
towards increased rates of major and non-major clinic-
ally relevant bleeding in patients >75 years of age with
both doses compared with placebo. In Hokusai-VTE, a
total of 1104 patients aged >75 years were enrolled. In this
subgroup, efficacy and safety outcomes were similar be-
tween patients receiving edoxaban 60 mg od or warfarin
[39].
Patients with renal impairment
All the direct oral anticoagulants are excreted renally to
some extent; therefore, reduced renal function can result
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an associated increased risk of bleeding.
All published studies to date examining the direct oral
anticoagulants for either the initial treatment or second-
ary prevention of VTE have excluded patients with se-
vere renal impairment, defined as a calculated CrCl
of <30 ml/min in the rivaroxaban, edoxaban and dabiga-
tran studies, and of <25 ml/min (or a serum creatinine
level of >2.5 mg/dl) in the trials examining apixaban
[32,33,35-37]. Between ~5% and 10% of patients in the
studies of direct oral anticoagulants (EINSTEIN studies of
rivaroxaban, AMPLIFY/AMPLIFY-EXT studies of apixa-
ban, Hokusai-VTE study of edoxaban and RE-COVER
studies of dabigatran) had moderate renal impairment
(CrCl 30–50 ml/min). Published supplementary data for
the initial VTE treatment studies reported no statistically
significant differences in efficacy and safety of the direct
oral anticoagulants administered at standard doses in this
patient group compared with those with normal renal
function; however, the number of patients was small.
Assessment of renal function is recommended before
initiating treatment with any of the direct oral anti-
coagulants, and in patients on long-term treatment when
conditions arise that may affect renal function [58]. Al-
though a lower dose of rivaroxaban (15 mg od) has been
evaluated for the prevention of stroke in patients with
atrial fibrillation (AF), and is recommended for patients
with moderate (CrCl 30–49 ml/min) or severe (CrCl
15–29 ml/min) renal impairment [40,59], this has not
been studied in a clinical setting for the treatment of VTE.
The European Medicines Agency (EMA), therefore, only
recommends a dose reduction to 15 mg od for the sec-
ondary prevention of VTE in patients with moderate to
severe renal impairment if the risk of bleeding outweighs
the risk of recurrent VTE (based on pharmacokinetic
modelling data) [40]. Because of the lack of efficacy data,
the US Food and Drug Administration (FDA) suggests
avoiding the use of rivaroxaban in patients with CrCl
<30 ml/min, and does not recommend dose adjustment
based on renal function in the VTE treatment indica-
tion [59]. Dabigatran is contraindicated in Europe for
patients with severe renal impairment, and a dose re-
duction to 75 mg bid is recommended by the FDA for
stroke prevention in patients with non-valvular AF and
CrCl 15–30 ml/min (based on pharmacokinetic model-
ling data). Dose reductions are also recommended by the
EMA for patients with moderate renal impairment.
[44,60]. For apixaban, use in its current indications is not
recommended in patients with a CrCl <15 ml/min, and
dose reduction is only recommended in patients with
non-valvular AF with at least two of the following charac-
teristics: age ≥80 years, body weight ≤60 kg or serum cre-
atinine ≥1.5 mg/dl [61]. Reduced dosing was not part of the
study design in the RE-COVER and AMPLIFY trials[34,35], but in Hokusai-VTE edoxaban given at a halved
dose of 30 mg od for patients with CrCl 30–50 ml/min
was associated with similar efficacy to standard of care,
together with a significant reduction in major and non-
major clinically relevant bleeding [39].
Pregnant patients
Although not yet evaluated extensively in pregnancy,
based on limited data and their small molecular weight
[40,58], it is likely that all the direct oral anticoagulants
cross the placenta and, therefore, have the potential for
teratogenicity and unwanted foetal anticoagulant effects.
Therefore, LMWH or UFH remain the agents of choice
for VTE during pregnancy or breastfeeding, because nei-
ther of these agents crosses the placental barrier or is se-
creted in breast milk [26]. Warfarin is contraindicated
during pregnancy owing to its teratogenic effects, par-
ticularly during weeks 6–13 of gestation, but can be
taken while breastfeeding [26].
Patients with active malignancy
Active malignancy is a significant risk factor for throm-
bosis and is present in ~20% of cases of VTE. The
development of VTE is known to increase mortality
rates and treatment costs for patients with cancer [17].
Extended treatment with LMWH for at least 6 months
is the treatment of choice for patients with malignancy-
associated VTE, owing to the finding of a ≤50% reduc-
tion in the risk of recurrent thrombosis with this
approach compared with warfarin. In published trials
examining the direct oral anticoagulants for the treat-
ment of VTE, ~5% of patients had active malignancy at
the time of enrolment; therefore, the experience to date
with the direct oral anticoagulants in patients with can-
cer is limited. In all these studies, patients in the com-
parator arm received warfarin rather than LMWH for
extended treatment. [25]. The largest dataset of patients
with cancer from studies of direct oral anticoagulants
for the treatment of VTE comes from a pooled analysis
of the EINSTEIN DVT and EINSTEIN PE studies. A
total of 655 patients with active cancer (at baseline or di-
agnosed during the study) and 469 patients with a his-
tory of cancer were randomized. Patients received either
rivaroxaban 15 mg bid for 21 days then 20 mg od, or
enoxaparin 1 mg/kg bid overlapping and transitioning to
warfarin or acenocoumarol (INR 2.0–3.0) for 3, 6 or
12 months. In patients with active cancer (diagnosed at
baseline or during treatment), the incidence of recurrent
venous thromboembolic and clinically relevant bleeding
events were numerically lower in patients allocated to
rivaroxaban compared with patients assigned to enoxa-
parin/VKA (5% vs 7%; HR 0.67; 95% CI 0.35–1.30 and
14% vs 16%; HR 0.80; 95% CI 0.54–1.20, respectively).
Patients with active cancer receiving rivaroxaban had a
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those receiving standard therapy (2% vs 5%; HR 0.42;
95% CI 0.18–0.99), whereas the incidence of all-cause
death was similar between the rivaroxaban and standard
therapy groups (16% vs 18%; HR 0.93; 95% CI 0.64–1.35).
Overall, rivaroxaban had a significant advantage compared
with enoxaparin/VKA in patients with active cancer with
regard to major bleeding and net clinical benefit, consist-
ent with the overall result of the pooled analysis of the
EINSTEIN DVT and EINSTEIN PE studies [41,62]. Using
data from AMPLIFY, a subgroup analysis was performed
to compare the efficacy and safety of apixaban (10 mg bid
for 7 days followed by 5 mg bid) with conventional treat-
ment (enoxaparin 1 mg/kg bid for at least 5 days
followed by dose-adjusted warfarin [target INR 2.0–3.0])
in patients with and without active cancer at baseline.
In patients with active cancer at baseline (3.1% of the
total randomized population; N = 5395), recurrent VTE
occurred in 3/81 (3.7%) patients in the apixaban group
and in 5/78 (6.4%) patients in the conventional treat-
ment group (RR 0.56; 95% CI 0.13–2.37); major bleeding
occurred in 2/87 (2.3%) and 4/80 (5.0%) patients, re-
spectively (RR 0.45; 95% CI 0.08–2.46). Although the
number of cancer patients was small, the results of this
prespecified subgroup analysis suggest that apixaban is
as effective as conventional therapy utilizing warfarin in
patients with both VTE and active cancer, and is associ-
ated with fewer bleeding events [63]. It should be em-
phasized that there are no current data directly
comparing the direct oral anticoagulants with continued
therapy with LMWH in patients with malignancy-
associated thrombosis.
Low or high body weight
Although specific data for the use of direct oral anti-
coagulants in patients with very low or very high body
weight are lacking, no exclusion criteria for body weight
have been specified in published phase III trials [32,33,35].
A subgroup analysis of the EINSTEIN DVT study found
that rivaroxaban had consistent efficacy and risk of bleed-
ing across body weight categories [32]. Supplementary
data from the apixaban studies reported similar findings
[34,37], as did pooled results from the RE-COVER trials
for the primary efficacy outcome (subgroup safety out-
comes were not reported) [36]. All studies enrolled limited
numbers of patients with low body weight, defined as ei-
ther <50 kg or ≤60 kg. For this reason, and because of the
potential to overestimate renal function in patients with
low body weight when using standard measurements such
as glomerular filtration rate [64], care should be taken in
administering the direct oral anticoagulants to patients
with very low body weight, despite dose adjustment not
being routinely recommended in the product information
[40,42,44].The impact of concomitant medications
Although the direct oral anticoagulants have consider-
ably fewer drug interactions than VKAs, certain drugs
may interfere with their metabolism and elimination.
Apixaban, rivaroxaban and dabigatran are substrates of
P-glycoprotein, and apixaban and rivaroxaban are also
substrates of cytochrome P450 3A4. Inhibitors or in-
ducers of these enzymes have the potential to interact
with these anticoagulants; therefore, caution is re-
quired when treating patients with such medications
[40,42,44].
Administration of other anticoagulant drugs should be
avoided with all the direct oral anticoagulants. Concur-
rent use of acetylsalicylic acid (ASA) has been shown to
increase the risk of haemorrhage in patients with AF
treated with the direct oral anticoagulants. Concomitant
use of ASA should be restricted to carefully selected pa-
tients in whom there is a clear indication for ongoing
antiplatelet therapy. As with warfarin, concurrent use of
the direct oral anticoagulant agents with both ASA and a
P2Y12 inhibitor is associated with a significant increase in
bleeding risk; therefore, triple therapy should be avoided
where possible or given for the minimum duration pos-
sible [65]. A post hoc analysis assessed the impact of
combined anticoagulant and ASA or non-steroidal anti-
inflammatory drug (NSAID) therapy on bleeding risk
compared with anticoagulant therapy alone in patients
enrolled in EINSTEIN DVT and EINSTEIN PE. The
safety population of the EINSTEIN DVT and PE studies
comprised 8246 patients (4130 assigned to rivaroxaban
and 4116 assigned to enoxaparin/VKA); of these pa-
tients, 1884 (22.8%) and 1202 (14.6%) received con-
comitant ASA or NSAID therapy at any time during
their study treatment, respectively. During NSAID/anti-
coagulant concomitant treatment, clinically relevant
and major bleeding occurred with an event rate of 37.5
per 100 patient-years versus 16.6 per 100 patient-years
during anticoagulant use only (HR 1.77; 95% CI 1.46–2.14)
and 6.5 per 100 patient-years versus 2.0 per 100 patient-
years during anticoagulant use only (HR, 2.37; 95% CI
1.51–3.75), respectively. Similarly, during ASA/anti-
coagulant concomitant treatment, clinically relevant and
major bleeding occurred with an event rate of 36.6 per 100
patient-years versus 16.9 per 100 patient-years during anti-
coagulant use only (HR 1.70; 95% CI 1.38–2.11) and 4.8
per 100 patient-years versus 2.2 per 100 patient-years dur-
ing anticoagulant use only (HR 1.50; 95% CI 0.86–2.62),
respectively. Increases in the risk of clinically relevant and
major bleeding were similar for rivaroxaban and enoxa-
parin/VKA treatment regimens. These data indicate that
physicians should inform patients about the potential
for increased bleeding with concomitant use of NSAIDs
or ASA and advise them on their treatment accordingly
[66].
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When considering the practical differences between dir-
ect oral anticoagulant and VKA therapy, all four direct
oral agents have the advantage of not requiring routine
coagulation monitoring along with fixed-dose regimens.
Therefore, these agents offer simplified, more convenient
therapy for VTE compared with conventional standard
of care. Poor INR control with VKA therapy can result
in sub-therapeutic anticoagulation, increasing the risk of
recurrent VTE or bleeding complications. It has also
been demonstrated that sub-optimal anticoagulation
with warfarin therapy may be associated with a risk of
PTS in patients with DVT [67]. The results of small
studies suggest that continued treatment with LMWH is
associated with a reduction in the risk of PTS, possibly
as a result of improved consistency of anticoagulant ef-
fect during the initial treatment period [68]. It is theoret-
ically possible that the potential for reduced variability
in anticoagulant effect with the direct oral anti-
coagulants may result in a similar benefit; however, to
date, the incidence of PTS has not been reported in tri-
als of the direct oral anticoagulants and further studies
are required to test this hypothesis.
While the lack of a need for routine coagulation moni-
toring is an advantage for the majority of patients, the ab-
sence of a regular measure of drug effect or plasma levels
means that patient compliance is difficult to assess. Pa-
tients who have a history or tendency of non-compliance
may be better suited to VKA therapy with regular INR
monitoring to reinforce compliance, although this may re-
quire additional resources such as domiciliary nurse visits
to measure INR. INR is not a valid measure to assess the
anticoagulant activity of the direct OACs; however, it
should be noted that tests are available for both qualitative
and/or quantitative measurement of direct oral anti-
coagulants if assessment of drug exposure is required in
certain clinical situations or patient populations [69].
The activated partial thromboplastin time may provide
a qualitative assessment of dabigatran plasma levels [70],
although limitations include high interindividual variabil-
ity and variability due to testing equipment used [71-73].
Alternatively, quantitative assessment can be obtained
through the HEMOCLOT® assay: a diluted thrombin time
test with appropriate calibrators for the measurement of
dabigatran plasma levels [70].
For rivaroxaban, the prothrombin time may provide a
qualitative assessment of drug exposure when rivaroxa-
ban-sensitive reagents are used, although the sensitivity of
the assay varies between reagents. A quantitative measure
of rivaroxaban levels can be obtained using an anti-Factor
Xa chromogenic assay with commercially available cali-
brators and controls. Both low and high plasma levels can
be measured with acceptable inter-laboratory precisionusing this quantitative approach [74]. Anti-Factor Xa
chromogenic assays with specific calibrators can also pro-
vide quantitative measurements of apixaban plasma levels
[75]. For all direct oral anticoagulants, it is important to
note that the interval between the last dose and blood
sampling time, in addition to renal function status, must
be considered when interpreting the test results.
A concern of many physicians regarding the use of
anticoagulation is the current lack of a reversal agent and
the impact that this may have in situations such as life-
threatening bleeding events or in patients who require ur-
gent surgery. VKAs represent the leading cause of hospital
admission for adverse events [76], and hospitalization due
to intracranial haemorrhage (ICH) in patients treated with
VKAs is associated with a high in-hospital mortality rate
[77,78]. Currently, supportive care measures such as ad-
equate hydration, appropriate transfusion support, and if
possible the identification and control of the site of bleed-
ing, are recommended as the mainstay of management for
bleeding occurring in patients receiving direct oral anti-
coagulants [79]. It should be noted that because of the
relatively short half-life of these agents, there is minimal
anticoagulant effect 24 hours after an initial dose or
12 hours after bid dosing, provided renal impairment is
not present. The clinical evidence for the use of pro-
haemostatic agents, such as activated or non-activated pro-
thrombin complex concentrates or recombinant Factor
VIIa, is still limited to a small number of case reports and
preclinical data or studies in healthy subjects, and these
products should only be given consideration in cases of
life-threatening bleeding [79]. A phase II study with a re-
combinant Factor Xa protein (PRT064445, andexanet alfa)
as a specific reversal agent for rivaroxaban is ongoing. In-
terim results have been reported [80], and enrolment has
begun in a phase III study of its safety and efficacy [81].
Phase III studies with rivaroxaban (ANNEXA-R) and
apixaban (ANNEXA-A) are also underway. RE-VERSE AD
(RE-VERSal Effects of Idarucizumab on Active Dabigatran)
is a phase III, interventional, open-label trial to evaluate the
reversal of the anticoagulant effects of dabigatran. In this
trial, 5.0 g i.v. idarucizumab is administered to patients
treated with dabigatran etexilate who have uncontrolled
bleeding or require emergency surgery or procedures
(NCT 02104947).
The incidence of critical site bleeding events repre-
sents an important measure in clinical studies on anti-
coagulants, as the risk of mortality after a bleeding event
is closely related to the site of haemorrhage. For ex-
ample, non-access-site bleeding events may have a more
significant impact on the likelihood of death than
access-site bleeding events [82]. ICH is a rare yet devas-
tating adverse event related to anticoagulation treatment
that can lead to severe disability and mortality. In an
analysis of the 30-day survival rate of patients with AF
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ated with an increased mortality from ICH compared
with patients receiving no anticoagulation (OR 1.62; 95%
CI 0.88–2.98), despite the availability of vitamin K and
fresh frozen plasma for the reversal of VKA activity [83].
In studies examining rivaroxaban, apixaban and dabiga-
tran for the prevention of stroke in patients with AF, all
three agents demonstrated a reduced risk of ICH com-
pared with warfarin. In the EINSTEIN PE, AMPLIFY,
Hokusai-VTE and RE-COVER trials, which reported on
ICH as a separate endpoint, the incidence was lower
with the direct oral anticoagulants than with warfarin
(3/2412 [0.1%] vs 12/2405 [0.5%] patients in EINSTEIN
PE; 3/2676 [0.1%] vs 6/2689 [0.2%] in AMPLIFY; 5/4118
[0.1%] vs 18/4122 [0.4%] in Hokusai-VTE; 0/1274
[0.0%] vs 3/1265 [0.2%] in RE-COVER), although this
was not assessed statistically [33-36,39]. Ongoing post-
marketing surveillance will be needed to clarify if this
potential advantage is confirmed in patients receiving
treatment for VTE and to further examine the case–fatal-
ity rate of major bleeding in patients receiving a direct oral
anticoagulant.
Real-world studies allow the risk of bleeding to be
assessed in routine clinical practice as opposed to the
controlled conditions of clinical studies. For example,
the prospective Dresden NOAC Registry, which enrols
patients indicated for at least 3 months’ anticoagulation
therapy with a direct oral anticoagulant, has recently
published results on the rates, management and out-
come of bleeding complications during rivaroxaban
therapy in daily care. Of the 2346 patients enrolled be-
tween October 2011 and December 2013, 575 were pre-
scribed rivaroxaban for VTE treatment, and the rate of
major bleeding for these patients was 4.1%/year (95%
CI 2.5–6.4) [84]. This incidence was higher than the
rate of major bleeding reported in the EINSTEIN stud-
ies (1.0% in total) [41]; however, patients in the Dresden
NOAC Registry were older and may have received lon-
ger durations of anticoagulant treatment and follow-up.
Of 1082 bleeding events across 762 patients with AF
and VTE, approximately 60% were managed conserva-
tively. Although approximately 40% of major bleeding
events required surgical or interventional treatment,
procoagulant therapy was rarely needed [84]. There is
scant real-life evidence data for the direct oral anti-
coagulants dabigatran, apixaban and edoxaban. A recent
retrospective cohort study compared the risk of gastrointes-
tinal (GI) bleeding in 374 patients, of whom 147 received
rivaroxaban and 227 dabigatran in a community hospital
setting. This first head-to-head study showed that GI
bleeding occurred in 5.3% of patients in the dabigatran
group compared with 4.8% of patients in the rivaroxaban
group (p = 0.8215). Both drugs had a higher bleeding risk
in the first 40 days. In particular, multivariate analysisshowed that the odds of experiencing a GI bleeding
event while on dabigatran for ≤40 days when compared
to ≥40 days was 8.3 (p < 0.0001). In the rivaroxaban
group, patients who were on the drug for ≤40 days had
a higher incidence of bleeding compared with those
taking the drug for >40 days (OR 2.8; p = 0.023) [85].
Conclusions
Anticoagulant therapy remains the central component
of the management of patients with VTE. Available data
confirm that the direct oral anticoagulants appear to
offer a realistic alternative to the traditional manage-
ment strategy of a parenteral anticoagulant followed by
a VKA. Further information from ongoing clinical trials
in patients treated with these agents will help clarify
the role of these drugs. As therapeutic choices widen,
clinical judgement regarding the optimal choice of anti-
coagulant based on individual patient characteristics
will become increasingly important.
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